JP2022535417A5 - - Google Patents

Info

Publication number
JP2022535417A5
JP2022535417A5 JP2021571944A JP2021571944A JP2022535417A5 JP 2022535417 A5 JP2022535417 A5 JP 2022535417A5 JP 2021571944 A JP2021571944 A JP 2021571944A JP 2021571944 A JP2021571944 A JP 2021571944A JP 2022535417 A5 JP2022535417 A5 JP 2022535417A5
Authority
JP
Japan
Prior art keywords
cells
macrophages
bone marrow
marrow cells
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021571944A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535417A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035703 external-priority patent/WO2020247372A1/en
Publication of JP2022535417A publication Critical patent/JP2022535417A/ja
Publication of JP2022535417A5 publication Critical patent/JP2022535417A5/ja
Pending legal-status Critical Current

Links

JP2021571944A 2019-06-04 2020-06-02 骨髄細胞炎症性表現型を調節するための抗ｓｉｇｌｅｃ－９組成物及び方法、ならびにその使用 Pending JP2022535417A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962857194P 2019-06-04 2019-06-04
US62/857,194 2019-06-04
US201962867577P 2019-06-27 2019-06-27
US62/867,577 2019-06-27
US202063032292P 2020-05-29 2020-05-29
US63/032,292 2020-05-29
PCT/US2020/035703 WO2020247372A1 (en) 2019-06-04 2020-06-02 Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Publications (2)

Publication Number Publication Date
JP2022535417A JP2022535417A (ja) 2022-08-08
JP2022535417A5 true JP2022535417A5 (https=) 2023-06-12

Family

ID=73653315

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021571944A Pending JP2022535417A (ja) 2019-06-04 2020-06-02 骨髄細胞炎症性表現型を調節するための抗ｓｉｇｌｅｃ－９組成物及び方法、ならびにその使用

Country Status (11)

Country Link
US (1) US20220396627A1 (https=)
EP (1) EP3980462A4 (https=)
JP (1) JP2022535417A (https=)
KR (1) KR20220042056A (https=)
CN (1) CN114401991A (https=)
AU (1) AU2020288824A1 (https=)
BR (1) BR112021024314A2 (https=)
CA (1) CA3142433A1 (https=)
IL (1) IL288511A (https=)
TW (1) TW202110890A (https=)
WO (1) WO2020247372A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021091885A2 (en) 2019-11-04 2021-05-14 Alector Llc Siglec-9 ecd fusion molecules and methods of use thereof
JP2023538590A (ja) * 2020-08-17 2023-09-08 サージ・セラピューティクス・インコーポレイテッド がんの処置のための骨髄由来抑制細胞機能の免疫調節
AU2023243622A1 (en) * 2022-03-31 2024-11-14 The Wistar Institute Of Anatomy And Biology Antibodies against human siglec-7 and use thereof for immunotherapy
KR20250035503A (ko) * 2022-03-31 2025-03-12 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 인간 Siglec-9에 대한 항체 및 이의 면역요법을 위한 용도
WO2024054527A1 (en) * 2022-09-06 2024-03-14 The Research Institute At Nationwide Children's Hospital Genetically engineered bone marrow derived myeloid cells for treatment of central nervous system tumors
AU2023411024A1 (en) * 2022-12-23 2025-08-07 The Wistar Institute Of Anatomy And Biology Siglec 9 inhibitors and methods of use thereof for enhancing immunotherapy efficacy
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒
CN117741143B (zh) * 2024-02-20 2024-05-07 首都医科大学附属北京地坛医院 Siglec-9蛋白及其特异性抗体在制备神经梅毒或神经损伤诊断产品中的应用
CN121281695B (zh) * 2025-12-11 2026-03-31 山东师范大学 用于药物发现的分子生成方法、系统、介质及设备

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001352977A (ja) * 2000-06-12 2001-12-25 Kirin Brewery Co Ltd 樹状細胞（ＤＣ）膜分子Ｓｉｇｌｅｃ−９に対する抗体、並びにそれを用いたＤＣ検出法及びＤＣ分離法
CN101035807A (zh) * 2004-06-09 2007-09-12 泰勒公司 Siglec－6相关疾病的诊断和治疗
GB0521991D0 (en) * 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
CA3003458A1 (en) * 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
AU2017207807A1 (en) * 2016-01-12 2018-07-12 Palleon Pharmaceuticals Inc. Use of Siglec-7 or Siglec-9 antibodies for the treatment of cancer
GB201611535D0 (en) * 2016-07-01 2016-08-17 King S College London Methods and compositions for treating cancer with siglec-9 activity modulators
AU2018298676A1 (en) * 2017-07-10 2019-12-19 Innate Pharma Siglec-9-neutralizing antibodies

Similar Documents

Publication Publication Date Title
JP2022535417A5 (https=)
JP2022535550A5 (https=)
JP7305704B2 (ja) Ｔ細胞療法のための診断方法
JP6788629B2 (ja) 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法
JP2022540768A5 (https=)
JP2021165291A (ja) Ｔ細胞療法のために患者をコンディショニングする方法
JP2026027390A (ja) 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療
ES2961666T3 (es) Métodos para determinar la dosificación de células CAR-T
JP2020054371A (ja) 末梢血から腫瘍反応性ｔ細胞の濃縮された集団を作製する方法
JP2021529753A5 (https=)
JP2023527410A5 (https=)
JP2020512983A (ja) 最適化された多機能性ｔ細胞を含むキメラ受容体ｔ細胞を使用する治療
US20240302349A1 (en) Methods of assessing or monitoring a response to a cell therapy
US20250313855A1 (en) Chimeric antigen receptor t cell therapy
JP2021510738A (ja) ４−１ｂｂと組み合わせたキメラ抗原受容体免疫治療製品の投与方法
TW202238129A (zh) Ｔ細胞療法
KR20190117014A (ko) 방광암의 항-pd-l1 항체 치료
JP2022539038A5 (https=)
EP3413890A1 (en) Histamine dihydrochloride combinations and uses thereof
WO2019232479A2 (en) Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods
JP2023501487A (ja) 白血球上での細胞表面マーカーの発現を制御するための抗Ｃｌｅｖｅｒ－１剤、および抗Ｃｌｅｖｅｒ－１に基づくがん治療を導くためのこれらの使用
EP3388073A1 (en) Targeting mesothelin in brain cancer
US20240158869A1 (en) Factors for optimizing immunotherapy
US20250161361A1 (en) Factors for optimizing immunotherapy efficacy
Thibaudin et al. 346 Translational program of the phase II MEDITREME trial: identification of prognostic factors for response to durvalumab and tremelimumab in combination with FOLFOX in metastatic colorectal cancer